approval
saveRINVOQ (UPADACITINIB) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalRINVOQ (UPADACITINIB) — FDA approvalOct 10, 2025 · 361d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalAug 12, 2025 · 420d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalMar 26, 2025 · 559d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 893d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 893d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalNov 14, 2023 · 1057d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalJun 22, 2023 · 1202d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalMay 18, 2023 · 1237d ago
same company · ±60 days · 6
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
- approvaldivalproex sodium DR: DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalMar 26, 2025
comments(0)
5-min edit window · permanent after that